In patients with type 2 diabetes at high cardiovascular (CV) risk, oral semaglutide demonstrated non-inferior cardiovascular safety to placebo, showing no significant increase in major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
In patients with type 2 diabetes and high cardiovascular risk, once-weekly semaglutide significantly reduced the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared to placebo, though it was associated with a higher risk of diabetic retinopathy complications.